Certara Q3 2025 Earnings Report

Certara EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.15
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Certara Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $104.53 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Certara Announcement Details

• Quarter: Q3 2025
• Date: 11/6/2025
• Time: After Market Closes
• Conference Call Date: Thursday, November 6, 2025
• Conference Call Time: 5:00PM ET

Certara (NASDAQ:CERT) is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services. Its software suite includes Phoenix WinNonlin for population pharmacokinetics and pharmacodynamics analysis, the Simcyp Simulator for physiologically based pharmacokinetic (PBPK) modeling, and the Cognigen clinical pharmacology services platform. On the services side, Certara provides regulatory strategy support, model-informed drug development (MIDD) consulting, real-world data analytics and bespoke simulation projects. These capabilities enable sponsors to address regulatory requirements, design efficient clinical trials and generate compelling evidence for product safety and efficacy.

Founded in 1993 as Pharsight and later rebranded Certara in 2014, the company has grown through organic innovation and strategic acquisitions to establish a global footprint. Headquartered in Princeton, New Jersey, Certara maintains offices and development centers across North America, Europe and the Asia Pacific region. The firm is led by a management team with deep expertise in pharmacometrics, regulatory science and technology innovation, supporting a diverse client base that ranges from emerging biotech firms to large multinational pharmaceutical companies.